The global sterile injectable sector is caught in an unprecedented multi-billion-dollar capacity squeeze. The skyrocketing demand for blockbuster GLP-1 metabolic therapies, complex biologics, and next-gen biosimilars has completely saturated the world’s commercial aseptic lines.
While legacy technical conferences spend days reading regulatory texts or debating lab validation, the Sterile Injectable Capacity, Expansion & Commercial Scale-Up Summit 2027 is built to do one thing: enable high-speed commercial execution.
Taking place right in the heart of Europe’s premier pharmaceutical manufacturing corridor—Düsseldorf—this summit is a dedicated, fast-paced commercial marketplace. We bring together the decision-makers holding the budgets to solve real-world industrial bottlenecks: scaling to hundreds of millions of units, financing massive capital projects, managing “Take-or-Pay” contractual risks, and securing heavy machinery.